Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1711 to 1725 of 8314 results

  1. Apraglutide for treating short bowel syndrome [ID6533]

    In development Reference number: GID-TA11695 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]

    Awaiting development Reference number: GID-TA11641 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Camlipixant for treating refractory or unexplained chronic cough [TSID12072]

    Awaiting development Reference number: GID-TA11707 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Lomitapide for treating homozygous familial hypercholesterolaemia in people 5 to 17 years [TSID 12085]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Eptinezumab for preventing cluster headache attacks TSID 12087

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Clindamycin for treating bacterial vaginosis in females aged 12 and older [TSID 12127]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]

    Awaiting development Reference number: GID-TA11698 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Lebrikizumab for treating atopic dermatitis in children [TSID12133]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation